Keywords: myriad, discontinues, mpc-7869, cancer, usa-based, genetics, says
Myriad discontinues MPC-7869 in cancer
Article | 15 January 2007
USA-based Myriad Genetics says that its drug candidate MPC-7869 (R-flurbiprofen) failed to meet its efficacy endpoints in a recent multicenter, 246 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
